亚米万塔马布加化学疗法在日本患者EGFR外20插入NSCLC
Satoru Kitazono1, Akira Ono2, Tetsuji Kawamura3
1Department of Medical Affairs, At Janssen Pharmaceutical K.K, Tokyo, Japan.
Cancer science
|September 9, 2025
概括
在日本患有非小细胞肺癌 (NSCLC) 的患者中,amivantamab加化学疗法显著改善了无进展的生存率,这些患者携带EGFR外基因组20插入突变. 这种组合疗法证明了有效性和安全性,支持其在这种NSCLC亚型的第一线治疗中使用.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 表皮生长因子受体 (EGFR) 插入突变 (EGFR Exon 20ins) 与非小细胞肺癌 (NSCLC) 的预后不佳有关.
- 这些突变赋予了对标准EGFR-tyrosine激酶抑制剂的耐药性,需要替代治疗策略.
研究的目的:
- 评估在日本患有NSCLC和EGFR Exon 20ins的患者中,amivantamab化疗与化疗的疗效和安全性.
- 评估amivantamab化疗作为这种特定NSCLC群体的第一线治疗的有效性.
主要方法:
- 一项涉及34名日本患者的PAPILLION第三期试验 (NCT04538664) 的亚群分析.
- 随机的1:1分配给静脉注射的amivantamab加上碳烯/pemetrexed化疗或单独的化疗.
- 主要终点:盲目独立中央审查的无进展生存率 (PFS);次要终点包括客观反应率和整体存活率.
主要成果:
- 平均PFS为15.5个月的amivantamab-化疗与5.6个月的单独化疗 (HR=0.22).
- 与化疗相比,amivantamab-化疗显示了二次终点的改善.
- 不良事件主要是可逆的血液和EGFR相关毒性;治疗中止不常见.
结论:
- 艾米万他马布化疗在日本NSCLC患者中表现出卓越的疗效和可管理的安全性,这些患者患有EGFR Exon 20ins.
- 结果与整体试验人群一致,支持作为一线选择的amivantamab化疗.
- 通过敏感方法早期识别EGFR Exon 20ins突变对于患者获得这种疗法至关重要.
相关概念视频
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
597
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
597
Tumor Immunotherapy
1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K


